FDA OKs NGS Test for Tumor Profiling and as CDx for Sunvozertinib in NSCLC
The Oncomine Dx Express Test may generate results in as little as 24 hours when used on the Ion Torrent Genexus Dx Integrated Sequencer.
YL201 Demonstrates Tolerability, Early Efficacy in Advanced Solid Tumors
Among 287 patients across multiple solid tumor indications, YL201 had an objective response rate of 40.8%, with a disease control rate of 83.6%.
FDA Approves SIR-Sphere Y-90 in HCC
SIR-Sphere Y-90 resin microspheres are the only approved radioembolization treatments in the US for both HCC and mCRC.
Best Practices for the Medical Oncology Boards
A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.
The CHALLENGE Trial Helps Redefine Adjuvant Therapy With Exercise in CRC
The CHALLENGE trial in CRC studied structured exercise and demonstrated a DFS benefit comparable to or exceeding oxaliplatin chemotherapy.
New ASTRO Guidelines Highlight RT in WHO Grade 4 Adult-Type Diffuse Glioma
Updated guidelines from ASTRO recommend various radiation therapy techniques for patients with WHO grade 4 adult-type diffuse glioma.
[18F]AIF-NOTA-PCP2 Shows PD-L1 Monitoring Potential in Head and Neck Cancer
No tracer-related adverse effects were observed in the study, with [18F]AIF-NOTA-PCP2 showing acceptable dosimetry in patients with head and neck cancers.
Zanidatamab Combo Has Meaningful Activity in HER2+ Gastroesophageal Cancer
Confirmatory data may support zanidatamab as an advancement in the treatment of HER2-positive advanced gastroesophageal adenocarcinoma.
Male Cancer Survivors in Physically Demanding Jobs Need More Support
Findings from a WeCanWork study showed that men who work laborious jobs need additional support during and after cancer treatment.
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
Advances in NSCLC Bring Excitement in the Lung Space
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
Obrixtamig Plus Topotecan Shows Tolerability, Efficacy in Advanced ES-SCLC
The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.
Taletrectinib Shows Positive Efficacy and Toxicity in ROS1+ NSCLC
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
Busulfan-Enhanced VRd Regimen Improves Efficacy in NDMM
Busulfan/melphalan elicited higher PFS among patients with ISS stage II or stage III disease, and melphalan-200 improved PFS in ISS stage I disease.
Unveiling Advances in GU Cancers: Insights from Oncology Decoded
Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.
Bemarituzumab Regimen Improves Survival in FGFR2b+ Gastric/GEJ Cancer
Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.
Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL
The EPCORE NHL-1 trial showed a 41% complete response rate with epcoritamab for patients with relapsed/refractory LBCL.
Video-Based Genetic Counseling Improves Comprehension in HBOC
In those being screened for hereditary breast and ovarian cancer syndrome, use of a video tool improved the duration of physician-led genetic counseling.
Taletrectinib Is Suitable for First- and Second-Line ROS1+ NSCLC
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC
Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma
The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.
3 Things You Should Know About Targeting NRG1 and Rare Drivers in Pancreatic Cancer
Explore the latest advancements in pancreatic cancer treatment, focusing on genetic mutations, targeted therapies, and emerging clinical strategies.
Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma
Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.
SonoClear System Earns Breakthrough Designation for Intracranial Procedures
The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.
Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC
Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.
Increasing Clinician Awareness of PIPAC May Help Increase Its Use
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
SGR-1505 Earns Fast Track Designation for R/R Waldenström Macroglobulinemia
The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.
![No tracer-related adverse effects were observed in the study, with [18F]AIF-NOTA-PCP2 showing acceptable dosimetry in patients with head and neck cancers.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F566910aff802a39d5d1afef401d33f429392d845-1200x886.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "No tracer-related adverse effects were observed in the study, with [18F]AIF-NOTA-PCP2 showing acceptable dosimetry in patients with head and neck cancers.")
